---

---

tags : Cancer    crawled time : 00:20   

save search

---

Philadelphia Phillies partner with the National Pediatric Cancer Foundation® for "Cut and Color Funds the Cure®"
Published: 2024-03-23 (Crawled : 00:20) - prnewswire.com
FNCTF | News | $11.16 130 |

Communications

| Email alert Add to watchlist
foundation cancer

---

Europe Cancer Diagnostics Market Sees Promising Growth Amid Rising Demand for Precision Diagnostics - Forecasts to 2031
Published: 2024-03-01 (Crawled : 00:20) - prnewswire.com
QGEN | $40.76 -1.83% 310K |

Health Technology

| Email alert Add to watchlist
QGEN | $40.76 -1.83% 310K |

Health Technology

| Email alert Add to watchlist
ILMN | $118.565 -3.5% 82K |

Health Technology

| Email alert Add to watchlist
CAJFF | $27.93 -3.91% 0 |

Electronic Technology

| Email alert Add to watchlist
CAJPY | $27.66 60K |

n/a

| Email alert Add to watchlist
HOLX | $75.48 -1.6% 77K |

Health Technology

| Email alert Add to watchlist
TMO | News | $574.13 -0.57% 260K |

Health Technology

| Email alert Add to watchlist
ABT | News | $106.535 -0.33% 510K |

Health Technology

| Email alert Add to watchlist
europe precision cancer diagnostics growth market

---

AMERICAN SKIN ASSOCIATION ANNOUNCES ITS 2024 FUNDING OPPORTUNITIES FOR SKIN CANCER & DISEASES
Published: 2024-02-02 (Crawled : 00:20) - prnewswire.com
SNY | News | $49.085 5.31% 1.2M |

Health Technology

| Email alert Add to watchlist
SNYNF | News | $94.0 -0.27% 0 |

Health Technology

| Email alert Add to watchlist
association cancer skin funding

---

Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Published: 2023-11-03 (Crawled : 00:20) - globenewswire.com
REPL | $5.975 -5.61% 36K |

Health Technology

| Email alert Add to watchlist
presentation cancer cell immunotherapy meeting skin trial results

---

Global Next Generation Cancer Diagnostics Market Projected to Reach $57.8 Billion by 2030
Published: 2023-08-18 (Crawled : 00:20) - prnewswire.com
NVSEF | News | $96.0 52K |

Health Technology

| Email alert Add to watchlist
NVS | News | $98.67 0.33% 260K |

Health Technology

| Email alert Add to watchlist
reach cancer global diagnostics market

---

ASCO: Gilead and Arcus's Cancer Immunotherapy Combo Faces Scrutiny Over Lower...
Published: 2023-06-03 (Crawled : 00:20) - biospace.com/
RCUS 4 | $14.89 -3.5% 49K |

Health Technology

| Email alert Add to watchlist
GILD | $66.69 -0.58% 850K |

Health Technology

| Email alert Add to watchlist
cancer immunotherapy

---

Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial
Published: 2023-06-03 (Crawled : 00:20) - globenewswire.com
EVAX | $4.13 2.7K |

Manufacturing

| Email alert Add to watchlist
evx-01 melanoma vaccine cancer technology trial

---

Insights on the Nicotine Gum Global Market to 2027 - Rising Instances of Lung Cancer and Other Respiratory Disorders Drives Growth
Published: 2023-01-21 (Crawled : 00:20) - prnewswire.com
JNJ | News | $147.46 -0.72% 820K |

Health Technology

| Email alert Add to watchlist
lung global respiratory cancer growth market

---

NIXON NATIONAL CANCER CONFERENCE TO EXAMINE CANCER RESEARCH BREAKTHROUGHS FROM PATIENT PERSPECTIVE
Published: 2022-11-18 (Crawled : 00:20) - prnewswire.com
FNCTF | News | $11.16 130 |

Communications

| Email alert Add to watchlist
research conference cancer

---

Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
Published: 2022-04-29 (Crawled : 00:20) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0 |

Health Technology

| Email alert Add to watchlist
orgovyx treatment approval cancer prostate cancer

---

MIRASOL: A Randomized, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine vs Investigator’s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor Alpha Expression
Published: 2022-03-19 (Crawled : 00:20) - immunogen.com
IMGN | News | $31.23 0.03% 49M |

Health Technology

| Email alert Add to watchlist
label one therapy cancer mirvetuximab phase 3

---

PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent, Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor Alpha Expression
Published: 2022-03-19 (Crawled : 00:20) - immunogen.com
IMGN | News | $31.23 0.03% 49M |

Health Technology

| Email alert Add to watchlist
phase 2 one cancer mirvetuximab

---

Mirvetuximab Soravtansine, a Folate Receptor Alpha Targeting Antibody-Drug Conjugate, in Combination with Bevacizumab in Patients with Platinum-Agnostic Ovarian Cancer: Final Analysis
Published: 2022-03-19 (Crawled : 00:20) - immunogen.com
IMGN | News | $31.23 0.03% 49M |

Health Technology

| Email alert Add to watchlist
drug ovarian cancer cancer mirvetuximab antibody

---

Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study
Published: 2022-03-19 (Crawled : 00:20) - immunogen.com
IMGN | News | $31.23 0.03% 49M |

Health Technology

| Email alert Add to watchlist
ovarian cancer results cancer mirvetuximab

---

Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer
Published: 2022-03-12 (Crawled : 00:20) - globenewswire.com
MYGN | $18.09 -2.9% 28K |

Health Technology

| Email alert Add to watchlist
bracanalysis diagnostic fda genetic lynparza fda approval approval cancer breast cancer

---

NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting
Published: 2021-11-13 (Crawled : 00:20) - globenewswire.com
NXTC | $1.44 5.1K |

Health Technology

| Email alert Add to watchlist
immunotherapy therapy cancer research

---

Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Published: 2021-11-13 (Crawled : 00:20) - globenewswire.com
IOVA 4 | $11.26 -3.84% 540K |

Health Technology

| Email alert Add to watchlist
immunotherapy therapy cancer iot

---

Modeling Data Showed Cologuard® Was Superior to Fecal Immunochemical Test (FIT) on Cost Effectiveness and Colorectal Cancer Incidence and Mortality
Published: 2021-05-21 (Crawled : 00:20) - biospace.com/
EXAS | $60.04 -5.06% 510K |

Health Technology

| -40.19% | O: 0.26% H: 2.45% C: 0.26%
test cancer colorectal cancer

---

Black Diamond Therapeutics Announces Preclinical Data Presentations on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting
Published: 2021-04-10 (Crawled : 00:20) - globenewswire.com
BDTX | $4.99 -1.38% 42K |

Health Technology

| Email alert Add to watchlist
presentation cancer research preclinical pre-clinical

---

Gainers vs Losers

45%

55%

Top 10 Gainers

SGBX | $0.26 80.43% 54M |

Producer Manufacturing

LICN | $1.0 78.57% 3.3M |

CSSE 4 | $0.2656 74.39% 9.7M |

Consumer Services

BRFH 4 | $1.89 71.82% 32M |

Manufacturing

ACON | $0.49 70.14% 24M |

n/a

BOF | $1.95 66.67% 920K |

MTC | $3.62 61.61% 790K |

Technology Services

AMST | $3.22 61.0% 720K |

Technology Services

PCSA | $2.28 40.74% 37M |

Producer Manufacturing

EVA | $0.626 39.14% 2.3M |

Process Industries

---

Your saved searches

---